Schwalbe Oliver, Buerger Cornelia, Plock Nele, Joukhadar Christian, Kloft Charlotte
Department of Clinical Pharmacy, Institute of Pharmacy, Freie Universitaet Berlin, Kelchstr. 31, D-12169 Berlin, Germany.
J Pharm Biomed Anal. 2006 Apr 11;41(1):233-9. doi: 10.1016/j.jpba.2005.11.017. Epub 2005 Dec 20.
During in vivo microdialysis studies time-consuming and laborious bedside calibration methods, e.g. retrodialysis, have to be performed. To reduce the burden on the patient it would be desirable to establish a reliable, time-saving calibration technique to obtain the in vivo recovery describing the relative drug transfer across the membrane of the microdialysis probe. The performed study aimed to evaluate and validate the use of urea as an endogenous reference compound to determine relative in vivo recovery of anti-infectives, e.g. linezolid used herein as model drug. In order to meet the special requirements imposed by microdialysis to measure urea concentrations in very small sample volumes ( approximately 10 microL) a photometric assay in 96-well microtiter plates was established based on the method of Berthelot. Subsequently, concentration- and flow rate-dependence were evaluated in vitro to determine the relative recovery (RR) of urea. Finally, urea and linezolid concentrations in human microdialysis samples were measured. The developed assay was validated according to international guidelines and met all requirements. Relative in vitro recovery was found to be independent from concentration and dependent on flow rate. Subsequently, relative in vivo recovery of urea was correlated with relative in vivo recovery of linezolid obtained by the traditional retrodialysis method. In healthy volunteers, the mean ratio of the relative recovery of linezolid to the relative recovery of urea was 0.6 for the subcutaneous (s.c.: CV 33.4%, n = 48) and 0.7 for the intramuscular probe (i.m.: CV 18.8%, n = 40), respectively. In critically ill patients this ratio was 0.7 for both tissues (s.c.: CV 32.8%, n = 18; i.m.: CV 22.1%, n = 17). Successful calibration of the urea reference technique without the need to use in vitro data will further promote the application of microdialysis in clinical studies especially in critically ill patients, as it reduces the imposed burden to a minimum.
在体内微透析研究过程中,必须采用耗时且费力的床边校准方法,例如反渗析法。为减轻患者负担,建立一种可靠、省时的校准技术以获得描述药物在微透析探针膜上相对转运的体内回收率是很有必要的。本研究旨在评估和验证使用尿素作为内源性参考化合物来测定抗感染药物(如本文用作模型药物的利奈唑胺)的相对体内回收率。为满足微透析在极少量样品体积(约10微升)中测量尿素浓度的特殊要求,基于贝托洛方法在96孔微量滴定板中建立了一种光度测定法。随后,在体外评估浓度和流速依赖性以确定尿素的相对回收率(RR)。最后,测量人体微透析样品中的尿素和利奈唑胺浓度。所开发的测定法根据国际指南进行了验证,并符合所有要求。发现体外相对回收率与浓度无关,而与流速有关。随后,尿素的相对体内回收率与通过传统反渗析法获得的利奈唑胺的相对体内回收率相关。在健康志愿者中,皮下(s.c.:CV 33.4%,n = 48)和肌肉内探针(i.m.:CV 18.8%,n = 40)的利奈唑胺相对回收率与尿素相对回收率的平均比值分别为0.6和0.7。在重症患者中,两种组织的该比值均为0.7(s.c.:CV 32.8%,n = 18;i.m.:CV 22.1%,n = 17)。无需使用体外数据即可成功校准尿素参考技术,这将进一步推动微透析在临床研究中的应用,尤其是在重症患者中,因为它将负担降至最低。